Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

Cigna Group will eliminate prescription drug rebates in many of its commercial health plans in 2027, a practice that has ...

Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...

As alternatives to intravascular lithotripsy, cutting balloon angioplasty and super-high-pressure non-compliant balloons were noninferior in the Short-CUT and VICTORY trials, as highlighted by the ...

Cancer therapies save lives but often cause neurologic damage, so we must recognize the full scope of neurotoxicity, from ...

Professor David Williams, a New Zealander working on gene therapy at UCLA, has warned that the Bill is “unfair to farmers” and based on false assumptions about precision and safety. He points to ...

The company said dosing in its Phase III MAGNITUDE-1 and MAGNITUDE-2 studies for transthyretin amyloidosis (ATTR) had been voluntarily paused after a patient in the cardiomyopathy trial was ...

It’s become a bit of a tradition for me to recap the Nobel Prizes in my column: In 2023, I covered Claudia Goldin’s work in ...

Science isn’t always serious. Sometimes researchers ask questions that seem silly at first, like why toast lands butter-side ...

BEVs carry diverse molecular cargo that offers non-invasive biomarkers for early diagnosis and monitoring of PCOS and ...

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasd ...

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics ...